24Sep 2017

RISK FACTORS FOR EARLY DEVELOPMENT OF POLYNEUROPATHY AMONG TYPE II DIABETIC PATIENTS.

  • Hala Mohammed Mahfouz, Professor of internal medicine and endocrinology, Ain-Shams University.
  • aHassan Ahmed Hashem, bYasser Hamed Mostafa: Lecturers of neurology, Al- Azhar faculty of medicine, Assiut branch.
Crossref Cited-by Linking logo
  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Polyneuropathy is one of the commonest complications of diabetes and the commonest form of neuropathy in the developed world. The development of neuropathy was associated with potentially modifiable risk factors such as serum lipids, hypertension, body mass index, and cigarette smoking. The aim of this study was to investigate the risk factors for distal symmetric sensory-motor polyneuropathy (DSP) in patients with type 2 diabetes mellitus (DM). Method: One hundred patients with type 2 DM (65 males and 35 females) were included in the study. In addition to a detailed neurological examination, the Michigan Neuropathy Screening Instrument was administered to all patients and nerve conduction examinations were performed for all patients. Results: Significant correlation between early development of DPN and BMI, hypertension, high serum cholesterol and poor glycemic control (high serum HbA1c). Conclusion: high BMI, hypertension, high serum cholesterol and poor glycemic control are risk factors for early development of polyneuropathy in type 2 diabetes mellitus.

  1. Deshpande AD, Harris-Hayes M and Schootman M: Epidemiology of diabetes and diabetes-related complications. Phys Ther 2008; 88: 1254?1264.
  2. Soliman E and Gellido C. Diabetic Neuropathy. eMedicine.com March 29, 2002.
  3. Boulton AJ, Vileikyte L, Ragnarson-Tennvall G and Apelqvist J. The global burden of diabetic foot disease. Lancet. 2005;366:1719?24.
  4. Boulton AJ, Cavanagh PR and Rayman G. The foot in diabetes. 4th ed. John Wiley & Sons Ltd; 2006.
  5. Vigersky RA. An overview of management issues in adult patients with type 2 diabetes mellitus. J Diabetes Sci Technol. 2011; 5(2): 245?250.
  6. Sanghera DK and Blackett PR. Type 2 diabetes genetics: J Diabetes Metab. 2012; 3(198): pii6948.
  7. Edwards JL, Vincent AM, Cheng HT and Feldman EL: Diabetic neuropathy: mechanisms to management. Pharmacol Ther 2008; 120: 1? 34.
  8. Kendall FP and McCreary EK. Muscles: testing and functions with posture and pain. Baltimore: Lippincott Williams & Wilkins; 2005.
  9. Smith AG and Singleton JR. Obesity and hyperlipidemia are risk factors for early diabetic neuropathy. J Diabetes Complications. 2013; 27: 436-442.
  10. National Diabetes Information Clearinghouse (2012). Retrieved 5/6/12:
  11. Tesfaye S., Chaturvedi N., Eaton S.E. and et al; Vascular risk factors and diabetic neuropathy. N. Engl. J. Med. 2005; 352, 341?350.
  12. Booya F, Bandarian F, Larijani B, and et al; Potential risk factors for diabetic neuropathy: a case control study BMC. Neurology 2005: 5-24
  13. American Diabetes Association. Position statement: standards of medical care for patients with diabetes mellitus. Diabetes Care 2002; 25:33-49.
  14. Feldman EL and Stevens MJ. Clinical testing in diabetic peripheral neuropathy. Can J Neurol Sci. 1994; 21:3-7.
  15. Oh S. Anatomical guide for common nerve conduction studies. Oh Shin MD, editor. Clinical Electromyography: Nerve Conduction Studies i?inde. 1. Baskı. Baltimore: Park Press; 1984; s. 65-85.
  16. England JD, Gronseth GS, Franklin and et al; American Academy of Neurology; American Association of Electrodiagnostic Medicine; American Academy of Physical Medicine and Rehabilitation. Distal symmetric polyneuropathy: a definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2005; 64:199-207.
  17. Barbosa AP, Medina JL, Ramos EP and Barros HP. Prevalence and risk factors of clinical diabetic polyneuropathy in a Portuguese primary health care population.?Diabetes Metab.?2001;27:496?502.
  18. Ashok S, Ramu M, Deepa R and Mohan V. Prevalence of neuropathy in type 2 diabetic patients attending a diabetes centre in South India.?J Assoc Physicians India 2002;50:546?50.
  19. Janghorbani M, Rezvanian H, Kachooei A and et al; Peripheral neuropathy in type 2 diabetes mellitus in Isfahan, Iran: Prevalence and risk factors.?Acta Neurol Scand.?2006;114:384?91.
  20. M?rkrid K,?Ali L?and?Hussain A: Risk factors and prevalence of diabetic peripheral neuropathy: A study of type 2 diabetic outpatients in Bangladesh Int J Diabetes Dev Ctries. 2010; 30 (1): 11?17.
  21. Sharon g. Bruce and? Kue Young: Prevalence and Risk Factors for Neuropathy in a Canadian First Nation Community Diabetes Care 2008; 31:1837?1841.
  22. Loprinzi PD, Kathy K. Hager and Pradeep Y. Ramulu: Physical activity, glycemic control, and diabetic peripheral neuropathy:A national sample Journal of Diabetes and Its Complications 2014; 28: 17?21.
  23. Bruce DG, Davis WA and Davis TM. Longitudinal predictors of reduced mobility and physical disability in patients with type 2 diabetes: the Fremantle Diabetes Study. Diabetes Care 2005; 28: 2441-2447.
  24. Kluding PM, Pasnoor M, Singh R and et al. The effect of exercise on neuropathic symptoms, nerve function, and cutaneous innervation in people with diabetic peripheral neuropathy. J Diabetes Complications 2012; 26: 424-429.
  25. Balducci, S., Iacobellis, G., Parisi, L. and et al. Exercise training can modify the natural history of diabetic peripheral neuropathy. Journal of Diabetes and its Complications 2006; 20(4): 216?223.
  26. Tuttle, L. J., Hastings, M. K., and Mueller, M. J. A moderate-intensity weight bearing exercise program for a person with type 2 diabetes and peripheral neuropathy. Physical Therapy 2012; 92(1): 133?141.
  27. Loprinzi, P. D. and Ramulu, P. Y. Objectively-measured physical activity and inflammatory markers among U.S. adults with diabetes: Implications for attenuating disease progression. Mayo Clinic Proceedings 2013; 88(9): 942?951.
  28. Loprinzi, P. and Cardinal, B., Crespo, C., et al. Objectively measured physical activity and C-reactive protein: National Health and Nutrition Examination Survey 2003?2004. Scandinavian Journal of Medicine & Science in Sports 2013; 23(2): 164?170.
  29. Sigal, R. J., Kenny, G. P., Wasserman and et al. Physical activity/exercise and type 2 diabetes: a consensus statement from the American Diabetes Association. Diabetes Care 2016; 29(6): 1433?1438.
  30. Li L, Chenb J, Wanga J and Caia D, Prevalence and risk factors of diabetic peripheral neuropathy in Type 2 diabetes mellitus patients with overweight /obese in Guangdong province, China primary care diabetes 2 0 1 5; 9: 191?195.
  31. Tesfaye S, Stevens LK, Stephenson JM, et al. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the Eurodiab IDDM complications study, Diabetologia 1996; 39: 1377?1384.
  32. Al-Mahroos F. and Al-Roomi K., Diabetic neuropathy, foot ulceration, peripheral vascular disease and potential risk factors among patients with diabetes in Bahrain: a nationwide primary care diabetes clinic-based study, Ann. Saudi Med. 2007; 27: 25?31.
  33. Al-Maskari F and El-Sadig M. Prevalence of risk factors for diabetic foot complications. BMC Fam Pract. 20017; 8: 59.
  34. Saadi H, Carruthers SG, Nagelkerke N and et al. Prevalence of diabetes mellitus and its complications in a population-based sample in Al Ain, United Arab Emirates. Diabetes Res Clin Pract. 2007; 78: 369-377.
  35. Hanssen KF. Blood glucose control and microvascular and macrovascular complications in diabetes. Diabetes 1997; 46(2): 101-103.
  36. Dyck PJ, Davies JL, Wilson DM and et al. Risk factors for severity of diabetic polyneuropathy: intensive longitudinal assessment of the Rochester Diabetic Neuropathy Study cohort. Diabetes Care 1999; 22: 1479-1486.
  37. Tesfaye S, Chaturvedi N, Eaton SEM and et al: Vascular risk factors and diabetic neuropathy. New Engl J Med 2005; 352: 341?350.
  38. Gregory JA, Jolivalt CG, Goor J and et al. Hypertension-induced peripheral neuropathy and the combined effects of hypertension and diabetes on nerve structure and function in rats. Acta Neuropathol 2012; 124: 561-573.
  39. De Visser A, Hemming A1, Yang C1 and et al. The adjuvant effect of hypertension upon diabetic peripheral neuropathy in experimental type 2 diabetes. Neurobiol Dis 2014; 62: 18-30.
  40. Katulanda P, Ranasinghe P, Jayawardena R and et al. The prevalence, patterns and predictors of diabetic peripheral neuropathy in a developing country. Diabetol Metab Syndr 2012; 4: 21.
  41. Kote GS, Bhat AN, Ismail MH and Gupta A. Peripheral insensate neuropathy-is height a risk factor? J Clin Diagn Res 2013; 7: 296-301.
  42. Callaghan B and Feldman E. The metabolic syndrome and neuropathy: therapeutic challenges and opportunities. Ann Neurol 2013; 74: 397-403.
  43. Boru U.T, Alp R, Sargin H. and et al. Prevalence of peripheral neuropathy in type 2 diabetic patients attending a diabetes center in Turkey, Endocr. J. 2004; 51:563?567.
  44. Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The New England Journal of Medicine 1993; 329(14): 977?986.
  45. Loprinzi PD, Hager KK and Ramulu PY: Physical activity, glycemic control, and diabetic peripheral neuropathy: Journal of Diabetes and Its Complications 2014; 28: 17?21.

[Mahfouz H.M, Hashem A.H. and Yasser Hamed Mostafa. (2017); RISK FACTORS FOR EARLY DEVELOPMENT OF POLYNEUROPATHY AMONG TYPE II DIABETIC PATIENTS. Int. J. of Adv. Res. 5 (Sep). 1001-1006] (ISSN 2320-5407). www.journalijar.com

Hassan Ahmed Hashem
lecturer of neurology, Al Azhar faculty of medicine

DOI:

Article DOI: 10.21474/IJAR01/5416      
DOI URL: http://dx.doi.org/10.21474/IJAR01/5416

Download Full Paper

Download PDF No. of Downloads: 4 | No. of Views: 53